Research group - Mikael Björnstedt

Denna sida på svenska

The main focus of the research group involves translational and clinical studies on the use of redox-active selenium compounds as cancer chemotherapeutics.

Cancer is a devastating disease with more than 1.25 million deaths yearly within the EU. The prevalence is increasing over the years. Despite improvements in the treatment of some cancers, there are no or very limited options to treat a large group of patients, particularly those diagnosed with cancer of the visceral organs. The latter group are characterized by advanced stage of disease upon diagnosis and inherent resistance to conventional cancer chemotherapy.

The research group focuses on targeting the redox axis of cancer cells survival - a relatively new cancer chemotherapeutic strategy. Certain redox-active selenium compounds have unique properties to target the redox imbalance and other survival pathways in cancer cells, hence “multi-target” in nature. These compounds can also efficiently kill tumour cells that are highly resistant to conventional cancer chemotherapy.

The group has an excellent national and international network with complementing expertise in order to perform preclinical studies and clinical trials. We have established advanced organotypic slice culture models, applicable to a large group of tumours, for studying the pharmacokinetics and pharmacodynamics of candidate chemotherapeutics with possible applications in personalized medicine.

The main projects:

  1. Clinical trials exploring the pharmacokinetics, pharmacodynamics, safety and efficacy of selenium compounds in the treatment of cancer.
  2. Studying the modes and mechanisms of anti-tumour actions of natural and synthetic selenium compounds and development of new strategies to increase the efficacy these selenium compounds in pre-clinical studies.
  3. Mechanistic studies focusing on drug actions and how selenium compounds specifically kill tumour cells.

Research group leader Mikael Björnstedt

Professor/senior physician

Mikael Björnstedt

Phone: 08-585 838 09
Organizational unit: Division of Pathology

Group members

Arun SelvamR&D trainee
Lena HernbergAssociated
Lisa ArodinPhD student
Mikael BjörnstedtProfessor/senior physician
Ola BrodinAssociated
Olof DanielssonAssociated
Rim JawadGraduate Student
Sougat MisraAssistant professor

Research techniques

  • Cell and tissue culture

  • Biochemical methods (enzymology, functional assessment of transcription factors, assay development)

  • Transcriptomics and proteomics

  • Histology and Immunohistochemistry

External funding

Cancerfonden, Cancer- och Allergifonden, Jochnick Foundation, Radiumhemmets Forskningsfonder, The County Council of Stockholm

Teaching assignments


Selected publications

Quantification of low molecular weight selenium metabolites in human plasma after treatment with selenite in pharmacological doses by LC-ICP-MS.
Flouda K, Dersch J, Gabel-Jensen C, Stürup S, Misra S, Björnstedt M, et al
Anal Bioanal Chem 2016 Mar;408(9):2293-301

Relatively high mortality risk in elderly Swedish subjects with low selenium status.
Alehagen U, Johansson P, Björnstedt M, Rosén A, Post C, Aaseth J
Eur J Clin Nutr 2016 Jan;70(1):91-6

Selenite in Cancer Therapy, In Diversity of Selenium Functions in Health and Disease
Sougat, M., Marita, W., Ola, B., and Mikael, B. (2015)
pp 109-136, CRC Press.

Redox-active selenium compounds--from toxicity and cell death to cancer treatment.
Misra S, Boylan M, Selvam A, Spallholz J, Björnstedt M
Nutrients 2015 May;7(5):3536-56

Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study.
Brodin O, Eksborg S, Wallenberg M, Asker-Hagelberg C, Larsen E, Mohlkert D, et al
Nutrients 2015 Jun;7(6):4978-94

Selenium cytotoxicity in cancer.
Wallenberg M, Misra S, Björnstedt M
Basic Clin. Pharmacol. Toxicol. 2014 May;114(5):377-86

Selenium induces a multi-targeted cell death process in addition to ROS formation.
Wallenberg M, Misra S, Wasik A, Marzano C, Björnstedt M, Gandin V, et al
J. Cell. Mol. Med. 2014 Apr;18(4):671-84

Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens.
Alehagen U, Johansson P, Björnstedt M, Rosén A, Dahlström U
Int. J. Cardiol. 2013 Sep;167(5):1860-6

Methylselenol formed by spontaneous methylation of selenide is a superior selenium substrate to the thioredoxin and glutaredoxin systems.
Fernandes A, Wallenberg M, Gandin V, Misra S, Tisato F, Marzano C, et al
PLoS ONE 2012 ;7(11):e50727

Extracellular thiol-assisted selenium uptake dependent on the x(c)- cystine transporter explains the cancer-specific cytotoxicity of selenite.
Olm E, Fernandes A, Hebert C, Rundlöf A, Larsen E, Danielsson O, et al
Proc. Natl. Acad. Sci. U.S.A. 2009 Jul;106(27):11400-5